CERTIFICATE OF ANALYSIS

PuriLab Analytical

Retatrutide 30 mg

RT-2026-129 Lot PED26090802 Analyzed November 14, 2026



TIMELINE

ORDERED
November 7, 2026

RECEIVED
November 13, 2026

ANALYZED
November 14, 2026

SAMPLE

NAME
Retatrutide 30 mg

EXPECTED
Retatrutide

AMOUNT
1 vial, lyophilized powder

TESTING

CLIENT
Jason Koerner

TEST TYPE
Content & purity

METHOD
HPLC-UV

CONTENT, HOW MUCH IS IN IT

60.20 mg

Label claim: 30 mg


PURITY, HOW CLEAN IT IS

>99.9%

Measured, not estimated. Purity is calculated from the full chromatogram shown above, and no impurity peaks were detected above the reporting threshold. Results of 99.95% or higher are reported as >99.9%, as 100% purity cannot be demonstrated analytically.

CHROMATOGRAM

HPLC-UV



● 17.80 min, Retatrutide, >99.9%

ANALYST COMMENTS

White lyophilized powder, red-cap vial, received sealed.

ANALYST SIGNATURE

Max Barrett
Lab Director, PuriLab Analytical
Analysis date: November 14, 2026

VERIFICATION CODE

RT-ZZQY-STCX

Verify at purilab.org/verify/RT-ZZQY-STCX

SCAN TO VERIFY

RT-ZZQY-STCX

Results apply solely to the sample as received and are not representative of any larger lot, batch, or production run. Findings are limited to the analytes stated above. PuriLab Analytical is an independent testing laboratory, is not CLIA certified or ISO 17025 accredited, does not sell or distribute any substance, and makes no representation as to the safety, legality, or fitness of any material for any use.